Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting

PHASE4CompletedINTERVENTIONAL
Enrollment

599

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

August 31, 2012

Conditions
NeoplasmsChemotherapy-Induced Nausea and Vomiting
Interventions
DRUG

Palonosetron Hydrochloride

0.25 mg IV\*1 dose on day 1, 30 minutes prior to the administration of the major chemotherapeutic agent.

DRUG

Palonosetron Hydrochloride

0.25mg IV\*3 doses on days 1,3 and 5,30 minutes prior to the administration of the major chemotherapeutic agent.

Trial Locations (18)

Unknown

Anhui Provincial Hospital, Hefei

Chinese Academy of Medical Sciences Cancer Hospital, Beijing

Chinese PLA 301 Hospital, Beijing

Chinese PLA 307 Hospital, Beijing

Chinese PLA Navy General Hospital, Beijing

Fuzhou General Hospital of Nanjing Military Command, Fuzhou

Guangxi Cancer Hospital, Nanning

The Second Xiangya Hospital of Central South University, Changsha

The First People's Hospital of Changzhou, Changzhou

Nanjing General Hospital of Nanjing Military Command, Nanjing

The First Affiliated Hospital of Soochow University, Suzhou

The Fourth People's Hospital of Wuxi, Wuxi

Shandong Cancer Hospital, Jinan

Shandong Provincial Hospital, Jinan

The Affiliated Hospital of Medical College Qingdao University, Qingdao

Shanghai Changzheng Hospital, Shanghai

Shanghai Xinhua Hospital, Shanghai

Tangdu Hospital of Fourth Military Medical University, Xian

All Listed Sponsors
collaborator

JiangSu Chia-Tai Tianqin Pharmacy Co.Ltd

UNKNOWN

lead

Shanghai Changzheng Hospital

OTHER

NCT01481831 - Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting | Biotech Hunter | Biotech Hunter